Sickle Cell Anemia
Autosomal Recessive Hemoglobinopathy
Primary risk age: Infants (Symptoms typically manifest after 6 months as fetal hemoglobin drops)
- Urgency
- Severe
- Typical age
- Infants (Symptoms typically manifest after 6 months as fetal hemoglobin drops)
- Body system
- Hematological System
Typical course: This is a lifelong chronic genetic disorder; acute pain crises last from days to a week.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Autosomal Recessive Hemoglobinopathy
Pathophysiology (Development Path)
Under conditions of low oxygen, dehydration, or infection, the abnormal hemoglobin S polymerizes, forming rigid, sickle-shaped red blood cells. These cells cannot deform to pass through microcapillaries, leading to vaso-occlusion, tissue ischemia, and infarction. The fragile sickle cells also undergo premature hemolysis, causing chronic anemia.
Primary Causes & Etiology
A point mutation in the beta-globin gene (HbS) on chromosome 11, resulting in the substitution of valine for glutamic acid.
2. Symptom Continuum
- Early Onset Signs
Dactylitis (hand-foot syndrome): painful swelling of the hands and feet in infants, accompanied by irritability and a low-grade fever.
- Progressive Phase
Chronic fatigue, pallor, mild jaundice (scleral icterus due to hemolysis), splenomegaly, and recurrent episodes of acute bone pain (vaso-occlusive crises).
- Severe Indicators
Acute Chest Syndrome: marked by chest pain, fever, tachypnea, cough, and new pulmonary infiltrates. Stroke, splenic sequestration crisis (sudden pooling of blood in the spleen causing hypovolemic shock), and aplastic crisis.
3. Clinical Verification
Newborn screening via hemoglobin electrophoresis or high-performance liquid chromatography (HPLC). DNA testing can confirm the genotype.
4. Care & Elements Plan
Primary Care Treatment Plan
Provide daily oral penicillin prophylaxis to prevent pneumococcal sepsis. Administer Hydroxyurea to increase fetal hemoglobin levels, reducing sickle cell formation. Manage acute pain crises with hydration and analgesics.
Home Support Elements
Ensure the child stays well-hydrated, especially during hot weather or exercise. Avoid extreme temperatures and high altitudes. Seek prompt care for any fever.
Generic Active Ingredients (No Brands)
- Penicillin V (generic prophylactic antibiotic active ingredient to prevent pneumococcal sepsis)
- Hydroxyurea (active ingredient to stimulate fetal hemoglobin production)
- Folic acid (generic active ingredient to support red blood cell production).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Any fever $ge 38.5^circ ext{C}$ in a child with sickle cell disease is a medical emergency requiring immediate evaluation and intravenous antibiotics.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
Avoid dehydration, hypoxia, extreme cold, and physical exhaustion. Genetic counseling is recommended for parents carrying the sickle cell trait.
Immunization Context
Up-to-date routine immunizations are critical, along with additional meningococcal and pneumococcal (PPSV23) vaccinations.
7. Timelines & Outlook
Active Timeline
This is a lifelong chronic genetic disorder; acute pain crises last from days to a week.
Expected Prognosis
Variable. This is a chronic, life-limiting condition. Survival has significantly improved with prophylactic penicillin and hydroxyurea, with many patients living into their 40s or 50s.
Potential Untreated Complications
Splenic infarction, recurrent infections, acute chest syndrome, stroke, osteonecrosis, and chronic organ damage (kidneys, lungs).
More in Red Blood Cell & Hemoglobin Pathologies
Beta-Thalassemia Major (Cooley's Anemia)
Autosomal Recessive Microcytic Hemolytic Anemia
Infants (Presents within the first 6 to 12 months of life as fetal hemoglobin declines)
G6PD Deficiency
X-Linked Red Blood Cell Enzymopathy
All ages (Inherited; typically triggered in infancy or childhood)
Iron Deficiency Anemia
Microcytic Hypochromic Anemia
Infants (9-24 months) and Adolescents (particularly females)